Agoracom Blog Home

Posts Tagged ‘CBD’

Primo Nutraceuticals $PRMO.ca Receives NPN (Natural Product Number) from Health Canada $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 4:42 PM on Friday, May 22nd, 2020

– Received its NPN (Natural Product Number) from Health Canada.

– Primo Nutraceuticals hand sanitizers meet Health Canada’s requirements for safety, effectiveness and quality.

– In response to the increasing demand for hand sanitizers in Canada during the current COVID-19 pandemic, Health Canada has implemented an interim expedited licensing approach to help businesses like Primo to obtain the required authorizations to produce and distribute hand sanitizer.

VANCOUVER, British Columbia, May 22, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce that it has received its NPN (Natural Product Number) from Health Canada. Primo Nutraceuticals hand sanitizers meet Health Canada’s requirements for safety, effectiveness and quality.

In response to the increasing demand for hand sanitizers in Canada during the current COVID-19 pandemic, Health Canada has implemented an interim expedited licensing approach to help businesses like Primo to obtain the required authorizations to produce and distribute hand sanitizer. Consistent with the interim measure for alcohol-based hand sanitizers currently in place, Primo’s hand sanitizer can be distributed to healthcare and commercial settings across Canada.

The Natural Product Number NPN 80099466 issued to Primo will be located on every Primo product label distributed.

The Natural Product Number contains information about the natural health product and found to be safe, effective and of high quality under their recommended conditions of use. You can identify licensed natural health products by looking for the eight-digit Natural Product Number (NPN) or Homeopathic Medicine Number (DIN-HM) on the label.

Sales are to commence in June 2020. No purchase orders are yet in place.

To view the product brochure visit: https://www.primoceuticals.com/shop#!/Primo-Lemon-Hand-Sanitizer-60/p/197662415/category=0

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis related products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of “Primo” branded retail outlets – offering “Thrive,” “Primo,” and a selection of curated partner brands. The Company possesses proprietary formulas for cannabis edibles, topical, and tinctures. Primo is focused on building a strong presence in the hemp industry with the objective of extracting and selling cannabinoids (CBD) products in both Canada and the United States.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

“Andy Jagpal”

President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected]

To learn more about what this news means to the shareholders visit:

https://t.me/PrimoNutraceuticals

Shop: www.primoceuticals.com

www.twitter.com/prmonutra

www.thrivecbd.org

www.beautykitchen.net

www.marianna.ca

www.drinkdefy.com

Corporate: www.primonutraceuticals.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c8349cf6-4f9e-49b2-9769-53f0c3274f0d

Primo Hand Sanitizer
Primo Nutraceuticals hand sanitizers meet Health Canada’s requirements for safety, effectiveness and quality.

Mota Ventures $MOTA.ca Talks Strategy on Mushrooms and CBD $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 9:30 AM on Thursday, May 21st, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

Results of the 2019 calendar year audit of Nature’s Exclusive:

  • Revenue of Cdn$29,034,000
  • Net income of $3,505,000
  • Achieved a margin of over 12%

VANCOUVER, BC / ACCESSWIRE / May 21, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) would like to thank all shareholders and investors for attending yesterday’s investor call. The main items addressed on the call were the completion of 2019 audit of the Nature’s Exclusive brand and the expansion of business in the natural health products sector through the proposed acquisition of Verrian.

The 2019 financial results for the Nature’s Exclusive brand is a strong indicator of the power of the Company’s eCommerce business model. This growth continued into 2020. For the months January through April 2020, the Company has generated revenue of Cdn$13,968,000 with related expenses of Cdn$13,514,000. Revenue has increased 188% for this time period over the same period during 2019. The Company’s customer acquisition and subscription retention strategies are yielding benefits through the year and into May where the Nature’s Exclusive brand has acquired over 17,613 customers from May 1st through May 18th. With over 60% of these customers electing into a subscription, the Company expects reduced costs in the following months, as customer acquisition expense is a one-time cost per customer.

As a leading business in the natural health products sector, we’ve been aggressively looking to expand our offering into growing segments of the market. Through this process, we identified psychedelic medicine as a unique opportunity, due to the overwhelming momentum of the sector and the incredible health benefits that can be obtained through derivative products.

The Company has come to terms to acquire Verrian, a leading company in the psychedelic medicine sector. Verrian owns and operates an established 110,000 square-foot pharmaceutical manufacturing facility in Germany that holds EU-GMP, ISO 14001, and narcotics manufacturing licenses. The facility and equipment of Verrian have been independently appraised at Cdn$10,600,000 and include an analytical laboratory and full pharmaceutical manufacturing suite.

Beyond the importance of this manufacturing asset, Verrian’s product commercialization process is already underway. The business has invested over Cdn$2,000,000 in clinical trials with two studies that are ongoing. These studies combined with our manufacturing abilities will uniquely prepare us to go-to-market once approval is granted.

Verrian’s product development pipeline is incredibly strong with two products named PSI Gen and PSI Gen+, which are both natural psilocybin extracts from organic mushrooms combined with metabolism-enhancing natural herbs. While there are many benefits patients may realize from utilizing psychedelic medicine, Verrian is focusing on opioid addiction reduction. This is an important mission as a company as it is estimated that over 13 million people in the world take opioids. For those individuals who have suffered a loss due to one’s addiction to a medically prescribed pharmaceutical, this holistic approach provided by Verrian and Mota is even more meaningful. In addition to treatments for opioids, new studies have demonstrated successful psilocybin treatments for both alcoholism and depression, substantially increasing the market size of potential patients. According to Marketdata, the United States market for alcohol and drug addiction rehab will be worth $42,000,000,000 in 2020, with over 15,000 private treatment facilities and growing.

“Our acquisition of Verrian is another step forward in executing our vision to use our powerful eCommerce platform for new and innovative natural health products. While we continue to grow and expand our CBD business units, we will also be ready to fully commercialize the technology created by Verrian. I look forward to working with Verrian’s incredibly talented team of clinical researchers and addiction medicine professionals within our existing ecosystem as it will uniquely position us as a leader in psychedelic medicine,” stated Ryan Hoggan, CEO of the Company.

Completion of the acquisition of Verrian remains subject to a number of conditions, including completion of due diligence, receipt of any required regulatory approvals and the negotiation of definitive documentation. For further information regarding the proposed acquisition, readers are encouraged to review the Company’s news release of May 19, 2020.

Conference replay

Canada/USA TF: 1-800-319-6413
International Toll: +1-604-638-9010
Replay Access Code: 4620

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President & CEO at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Empower $CBDT.ca Signs Term Sheet to Acquire Interest in Dosed Movie and Launches New #Psychedelics Company Dosed Wellness Ltd. $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 6:53 AM on Wednesday, May 20th, 2020
  • Empower enters into a term sheet to acquire an interest in the global royalty rights of Dosed Movie,
  • launches Dosed Wellness, a psychedelics brand,
  • launches new dedicated website www.dosedwellness.com and adds new team members dedicated to the new brand

VANCOUVER BC / May 20, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce it has entered into a non-binding term sheet with Golden Teacher Films Inc. (“Golden“) to acquire a 10% interest in certain royalty rights, intellectual property rights and interest in Dosed Movie (“DOSED”), an award-wining documentary film about treating anxiety, depression and addiction with psychedelic medicine.

Under the terms of the agreement, the Company intends to issue $75,000.00 CAD of common shares in the capital of Empower (each, a “Share”) plus an aggregate payment of $25,000.00 CAD to the Vendors at the Closing. Further, the principals of Golden, Tyler Chandler and Nicholas Meyers will be offered consulting contracts to join the management team of Dosed Wellness Ltd.

The Company also announces the launch of a dedicated psychedelics division Dosed Wellness Ltd. (“Dosed Wellness”) and a new dedicated website www.dosedwellness.com that will leverage the operating assets of Empower. Dosed Wellness is uniquely positioned as an early mover in the psychedelics space with a network of physicians and clinics, advanced research opportunities, telehealth capabilities, and a growing base of over 165,000 patients.

The mental health crisis could cost the world $16 trillion by 2030 and according to Future Market Insights; the global behavioral health (non-pharmacological) market is expected to be valued at US$156 billion by 2028.

“Widespread legalization of psilocybin and psychedelics is inevitable, as clinical research is showing these compounds are uniquely useful for treating mental illness and addiction.” said Tyler Chandler, Director of DOSED. “Since billions of people worldwide suffer from these conditions, we need to establish infrastructure and patient-care competencies to serve this population as soon as the law allows. We’re thrilled to align with Empower Clinics, which has the strategic vision, existing client base and clinic network to continue to lead the plant-based medicine industry.”

“The opportunity to partner with DOSED to help bring down stigmas and advance the science of psychedelic treatment options is a meaningful step forward to vastly improving the mental wellness outcome for millions of people around the world.” said Steven McAuley, Chairman and CEO of Empower. “Now, with the additions of Tyler and Nick on our new management team, we will leverage their substantial psychedelics experience and network to take full advantage of Empowers’ clinic infrastructure, technology and access to patients.”

According to the World Health Organization depression is already the leading cause of disability worldwide (more than 322 million people suffer from depression) and is a major contributor to the overall global burden of disease.

Both MDMA and psilocybin, combined with a course of therapy, have received Breakthrough Therapy Designation (BTD) from the FDA in the US, which means both are one step closer to licensing approval.

“Our team is well connected in the psychedelic space and our expertise on the media side will help elevate the Empower brand. We’re also excited that Empower Clinics is acquiring an interest in DOSED, as their promotion of the film will help educate millions of people about the opportunities inherent in psychedelic medicine.” said Nicholas Meyers, Producer of DOSED. “When people see Adrianne’s inspiring and eye-opening journey in DOSED, they’ll want to know how to access these treatments, which is precisely the problem Empower Clinics is positioned to solve as we move towards clinical trials and legalization.”

Psychedelic medicines derived from or inspired by plants and fungi found in nature have the potential to redefine how mental health conditions could be treated over the course of the next decade. Prohibition Partners Psych: The Psychedelics as Medicine Report March 2020

ABOUT EMPOWER

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company now offers COVID-19 testing options in the United States and physician-based consultations, to address COVID-19 concerns.

About Dosed Movie

After many years of prescription medications failing her, a suicidal woman turns to underground healers to try and overcome her depression, anxiety, and opioid addiction with illegal psychedelic medicine such as magic mushrooms and iboga. Adrianne’s first dose of psilocybin mushrooms catapulted her into an unexpected world of healing where plant medicines are redefining our understanding of mental health and addiction. DOSED is directed and produced by Tyler Chandler and Nicholas Meyers is producer and director of photography. Visit www.dosedmovie.com to rent or own DOSED.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley
Chairman & CEO
[email protected]
604-789-2146

Investors: Dustin Klein
SVP, Business Development
[email protected]
720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws.All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Mota Schedules Conference Call to Discuss Recent Announcements $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 5:20 PM on Tuesday, May 19th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / May 19, 2020 / MOTA VENTURES CORP. (CSE:MOTA)(FSE:1WZ)(OTC:PEMTF) (the “Company) a direct to consumer provider of a wide range of CBD products globally, is pleased to announce it will be hosting an investor conference call on Wednesday, May 20, 2020 with Mota Ventures management, Ryan Hoggan, CEO and Joel Shacker, President to discuss recent announcements.

The call will be held on May 20, at 1:15 pm Pacific Time.

Conference details:

Canada/USA TF: 1-800-319-4610
International Toll: 1-604-638-5340
Germany TF: 0800-180-1954

Callers should dial in 5 – 10 min prior to the scheduled start time and simply ask to join the call.

Conference replay

Canada/USA TF: 1-800-319-6413
International Toll: +1-604-638-9010
Replay Access Code: 4620

About Mota Ventures Corp.

Mota is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its First Class CBD and Nature’s Exclusive brands. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.
Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com.

Mota Ventures $MOTA.ca Announces Completion Of Audit For Nature’s Exclusive Brand $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 11:31 AM on Tuesday, May 19th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC, CANADA / ACCESSWIRE / May 19, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company“) is pleased to announce completion of an audit of the financial results of its Nature’s Exclusive brand through the twelve-months ended December 31, 2019.

  • 2019 audited financial results:
  • Revenue of Cdn$29,034,000
  • Associated expenses of Cdn$25,530,000
  • Net income of Cdn $3,505,000

“Completion of the 2019 audit is a culmination of an extensive team effort, and represents a significant milestone in the validation of our eCommerce business. The 2019 figures, where we achieved over 12% net income, provides us with a benchmark from which to measure our success in the 2020 fiscal year as we continue to build on the strong results generated by Unified,” noted Ryan Hoggan, Chief Executive Officer of the Company.

Throughout the 2019 calendar year, the Nature’s Exclusive brand was operated as a separate business segment of Unified Funding, LLC (“Unified“). The Company completed the acquisition of the brand, and the associated business line, on January 17, 2020. The audit was completed on carve-out financial statements of Unified, which present the standalone financial results of the brand. Figures presented in this news release were translated from US dollars into Canadian dollars using the Bank of Canada average annual exchange rate of US$1.00:Cdn$1.3269 for 2019.

The Company also announces that it has reached an agreement with Unified to amend the thresholds necessary for Unified to earn a bonus based on the financial results generated by the Nature’s Exclusive brand in the 2020 calendar year. Unified is entitled to earn a bonus payment based on the terms of the original transaction in which Mota acquired control of the brand, and the associated business line.

Under the terms of the amendment, Unified will continue to be entitled to a one-time bonus payment (the “Bonus Payment“) based on the revenue and profitability of Nature’s Exclusive in the 2020 calendar year. The Bonus Payment will be: (i) US$5,000,000, in the event gross revenue exceeds US$40,000,000 with a profit margin of at least ten percent; (ii) US$10,000,000, in the event gross revenue exceeds US$45,000,000 with a profit margin of at least ten percent; or (iii) US$15,000,000, in the event gross revenue exceeds US$50,000,000. The Bonus Payment will be payable in common shares of the Company (the “Bonus Shares“) based on an exchange rate of US$1.00 to C$1.30 and the greater of: (i) C$0.80; and (ii) the volume-weighted average closing price of the common shares of the Company on the Canadian Securities Exchange in the ten trading days prior to the last trading day of 2020. Any Bonus Shares issuable by the Company will be subject to the terms of a thirty-six month time release pooling arrangement, with applicable release dates calculated from the date of issuance of the Bonus Shares.

For further information regarding the Bonus Payment, and the acquisition of Nature’s Exclusive, readers are encouraged to review the Company’s news release of January 17, 2020.

“Revising the 2020 performance bonus will help to align our interests with Unified, and ensure they remain incentivized in the development of Nature’s Exclusive in the context of the current market. The brand has demonstrated strong financial results through 2020 to date, in spite of economic volatility and we look forward to continued success leading into the second half of 2020,” commented Ryan Hoggan, Chief Executive Officer of the Company.

About Mota Ventures Corp.

Mota is an established ecommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan

Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

North Bud Farms $NBUD.ca Announces Proposed Terms for Non-Brokered Private Placement of Units $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 9:19 AM on Tuesday, May 19th, 2020
  • Intends to complete a non-brokered private placement of units at a price of $0.05 per Unit for gross proceeds of up to C$2 million, subject to the Company’s receipt of minimum gross proceeds of C1$ million
  • Proceeds of the Offering will be used by the Company to meet its 12-month corporate and working capital requirements, which the Company believes is vital to ensuring efficient and consistent operations.

TORONTO, May 19, 2020 — North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company“) is pleased to announce that it intends to complete a non-brokered private placement of units (each a “Unit”) at a price of $0.05 per Unit for gross proceeds of up to C$2 million, subject to the Company’s receipt of minimum gross proceeds of C1$ million (the “Offering”).

Each Unit will be comprised of one common share in the capital of the Company (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Common Share (a “Warrant Share”) for a period of 24 months following the Closing Date (as defined below) at an exercise price equal to: (i) $0.075 if the Warrant is exercised within 12 months of the Closing Date, or (ii) $0.10 if the Warrant is exercised at any other time prior to expiry.

The Company may pay a cash fee or issue compensation securities to certain eligible finders in connection with the proceeds received by the Company from the sale of Units to subscribers introduced to the Company by such eligible finders.

The proceeds of the Offering will be used by the Company to meet its 12-month corporate and working capital requirements, which the Company believes is vital to ensuring efficient and consistent operations. Management believes that securing a 12-month cash runway is the most prudent step in attempting to secure the long-term viability of the Company. Failure to meet these capital requirements could force management to proceed with secondary options that may preserve less long-term value for shareholders. Subscription receipts will be held in escrow and released upon the filing of the Company’s 2019 financial statements.  The Offering is expected to close on or around June 1, 2020 (the “Closing Date”).

Anyone who is interested in participating in the current financing may email the Company at: [email protected]
The Offering is subject to certain conditions, including but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Canadian Securities Exchange (the “CSE”).

The Units will be offered: (i) on a private placement basis in all of the provinces and territories of Canada; (ii) in the United States on a private placement basis in reliance on Rule 506(b) of Regulation D or pursuant to other exemptions from the requirements of the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and in compliance with applicable United States federal securities laws and any “blue sky” laws or regulations of any state of the United States; and (iii) in such jurisdictions outside of Canada and the United States as determined by the Company on a private placement or equivalent basis.

Participation in the Offering will be open to anyone who qualifies under an accredited investor exemption and to existing shareholders (each an “Existing Shareholder”) of the Company as of the close of business on May 19, 2020 (the “Record Date”) who are eligible to participate in the Offering in reliance on the existing shareholder exemption under Canadian securities laws (the “Existing Shareholder Exemption”).

The aggregate acquisition cost to an Existing Shareholder relying on the Existing Shareholder Exemption cannot exceed $15,000 in any 12-month period, unless such Existing Shareholder has obtained advice regarding the suitability of the investment from a registered investment dealer in that Existing Shareholder’s jurisdiction. Persons who become shareholders of the Company after the Record Date are not permitted to participate in the Offering using the Existing Shareholder Exemption, however other exemptions may still be available.

The Units and any Warrant Shares issued upon the exercise of the Warrants issued in connection with the Offering will be subject to a statutory hold period in Canada of four months and one day following the Closing Date. Additional resale restrictions may apply under the laws of other jurisdictions.

This news release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, and these securities will not be offered or sold in any jurisdiction in which their offer or sale would be unlawful. The securities described herein have not been and will not be registered under the U.S. Securities Act, or any state securities laws of the United States. Accordingly, these securities will not be offered or sold to persons within the United States unless an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws is available.

In addition, the Company has resolved to re-price the 26.9M of currently issued and outstanding common share purchase warrants with exercise prices between $0.30/share and $0.40/share and various expiry dates, to a new reduced exercise price equal to $0.10 per share in order to align with the current proposed private placement and to encourage such warrant holders to exercise their warrants.  This reduction of warrant exercise prices is subject to certain conditions, including but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Canadian Securities Exchange (the “CSE”).

Additional Cost Cutting Measures

As of May 15, 2020, all members of senior management have been asked to agree to a 30% reduction in their cash-based compensation for the next four months, and to instead receive Common Shares in lieu.

The Company wishes to advise shareholders that it has successfully renegotiated approximately CDN$1 million in current payables by its subsidiary into a 24-month payment obligation. The restructuring improves the Company’s balance sheet and reduces monthly cash requirements moving forward. While this alleviates certain cash flow requirements, it does not affect the Company’s need to raise a minimum of $1 million of proceeds under the Offering.

Management Cease Trade Order Update

Additionally, the Company provides the following update on the previously announced management cease trade order (the “MCTO“) issued by the Ontario Securities Commission on March 31, 2020.

The MCTO was issued in connection with the delay by the Company in filing its annual financial statements, management’s discussion and analysis and related officer certifications for the financial year ended November 30, 2019 (collectively, the “Required Filings“) before the prescribed deadline of March 30, 2020.

The Company continues to work closely with its auditor and expects to file the Required Filings before the end of May 2020.

The Company is providing this status update in accordance with National Policy 12- 203 Management Cease Trade Orders (“NP 12-203“). The Company intends to follow the provisions of the Alternative Information Guidelines set out in NP 12-203, including the issuance of bi-weekly default status reports in the form of news releases, for as long as the Company remains in default. The Company confirms as of the date of this news release that there has been no material change in the information contained in the default announcement issued on March 13, 2020 and there is no other material information concerning the affairs of the Company that has not been generally disclosed.

Issuance of Common Shares for Services Rendered

The Company has proceeded with the issuance of 472,222 Common Shares, at an issue price of $0.18 per share, to an arm’s length advisor to the Company. The Common Shares, which are subject to a statutory hold period as required by applicable securities laws, are based upon the $85,000 cash value of the services rendered to the Company by the advisor.

About North Bud Farms Inc.

NORTHBUD owns and operates, through its subsidiaries, licensed cannabis facilities in Canada, California and Nevada. Bonfire Brands USA, the Company’s U.S. subsidiary, acquired cannabis production facilities in Salinas, California and Reno, Nevada in late 2019. The Salinas, California 11-acre farm is actively cultivating cannabis in its 60,000 sq. ft. of licensed greenhouse production space. The Reno, Nevada facility, located on 3.2 acres of land, was acquired through the acquisition of Nevada Botanical Science, Inc., and includes a world-class cannabis production, research and development facility with 5,000 sq. ft. of indoor cultivation space which holds medical and adult-use licenses for cultivation, extraction and distribution. Through its Canadian subsidiary, GrowPros MMP Inc., the Company built and owns a state-of-the-art purpose-built cannabis production facility located on 135 acres of agricultural land in Low, Quebec, Canada. The Low, Quebec facility currently has 24,500 sq. ft. of licensed indoor cultivation space; the Company has recently submitted its licence amendment application to Health Canada to add an additional 1,000,000 sq. ft. of outdoor cultivation space.

For more information visit: www.northbud.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements
Certain statements included in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the expressions “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “may”, “should” and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. This press release contains forward- looking statements that include, but are not limited to, statements related to the expected proceeds of the Offering, the completion of the Offering including the timing thereof, the intended use of proceeds from the Offering, the timing of the Company filing the Required Filings and the submission of the Company’s license application to Health Canada. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such risks and uncertainties include, among others, the risk factors included in North Bud Farms Inc.’s final long form prospectus dated August 21, 2018, which is available under the issuer’s SEDAR profile at www.sedar.com. 

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected] 

Mota Ventures $MOTA.ca Enters into Binding Term Sheet to Acquire 110,000 Square Foot European Pharmaceutical Manufacturer of Natural Psilocybin Products $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 12:47 PM on Saturday, May 16th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / May 16, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) announces that it has entered into a binding term sheet (the Term Sheet“), dated May 14, 2020, with Verrian Ontario Limited (“Verrian“), pursuant to which it proposes to acquire all of the outstanding share capital of Verrian (the “Transaction“). The Term Sheet replaces the previous preliminary letter of intent entered into with Verrian on May 11, 2020. Verrian is an arms’-length privately-held company that is focused on delivering and developing products related to addiction reduction, with a focus on alcohol and opiates.

ESTABLISHED EUROPEAN PSYCHEDELIC MEDICINE COMPANY

Verrian owns and operates an EU-GMP, ISO 14001 compliant 110,000 square foot pharmaceutical manufacturing facility in Radebeul, Germany. Verrian purchased the facility from a major global pharmaceutical manufacturer in 2019. Both the facility and equipment are independently appraised at Cdn$10,600,000, including an analytical laboratory, and full pharmaceutical manufacturing suite.

Verrian will operate three distinct business segments:

  • Pharmaceutical Manufacturing – A portfolio of medical & wellness products
  • Phyto API – API creation from medical plants
  • Analytical Testing – European Medicine Agency Standards

PRODUCTS FOCUSED ON OPIATE ADDICTION REDUCTION

Verrian’s singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of psilocybin demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance.

To date Verrian has developed two psilocybin products: PSI GEN and PSI GEN+. These Psilocybin products are focused on opiate addiction reduction. As natural psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs, they are ideal for individuals commencing micro-dosing and capable of being combined with additional anti-addiction therapies.

All of Verrian’s compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes.

GOALS AND VISION

In addition to the the facility and equipment outlined above, Verrian has invested approximately Cdn$2,400,000 in clinical trial design and development of proprietary formulations for its psilocybin trademarked PSI-GEN products, and cannabis products, including trademarked CBDaily and CBNight.

Verrian’s world renowned addiction medicine experts are moving ahead to develop new potential treatments for therapy, with rigorous clinical research. Once EU GMP and narcotics handling recertification are secured, capabilities will extend to: specialty pharmaceutical formulations; and psilocybin refinement and production for micro dosing.

“Signing this binding term sheet is an important step towards Mota’s goal of becoming a leader in the natural health space. Verrian’s significant investment into its licensing, research, equipment and facilities have made it one of the top psychedelic medicine companies. Mota is poised to capitalize on an emerging industry and will continue to expand its North American and European operations to ensure a strong distribution network is in place once this line of product is approved to go to market,” stated Ryan Hoggan, CEO of the Company.

The binding Term Sheet contemplates that the Company would acquire all of the outstanding share capital of Verrian in consideration for Cdn$20,000,000, which will be satisfied through the issuance of common shares (the “Consideration Shares“) to the existing shareholders of Verrian. The Consideration Shares will be issued at a deemed price of equivalent to the volume-weighted average closing price of the common shares of the Company in the ten trading days immediately prior to the entering into of definitive documentation in respect of the Transaction.

The Consideration Shares will be subject to terms of a thirty-six month time release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded. The Consideration Shares will be released from the pooling arrangement in tranches, of which ten-percent will be released after four months, fifteen percent after six months, and the balance in five equal tranches every six months thereafter. In addition to the Consideration Shares, upon closing of the Transaction, the Company will arrange for repayment of existing shareholder loans of Verrian totaling approximately Cdn$1,100,000.

The Company is at arms-length from Verrian, and each of its shareholders. The Transaction does not constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. Upon completion of the Transaction, an administrative fee of $422,000, payable in common shares of the Company, will be owing to a consultant who assisted with the Transaction.

The Transaction remains subject to a number of conditions, including completion of due diligence, receipt of any required regulatory approval and the negotiation of definitive documentation, which is expected to include warranties, representations, covenants, terms and conditions which are customary and consistent with industry standards for a transaction of this nature, as a well as a mutual break fee in the event of termination. The Transaction cannot be completed until these conditions have been satisfied.

We encourage shareholders and prospective investors to visit the Company’s AGORACOM Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Satavida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS
MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

The Canadian Securities Exchange has in no way passed upon the merits of the Transaction, and has neither approved nor disapproved the contents of this press release. Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

People are choosing #cannabis over cocktails because it’s healthier – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 6:05 PM on Friday, May 15th, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated cannabis company with products in 220 California dispensaries and joint ventures, licensing agreement & partnerships with global brands. The company recently closed $20 MILLION deal with Venom Extracts adding $CDN 16.4 million in revenue and $CDN 2.48 million in EBITDA. Learn More

People are choosing cannabis over cocktails because it’s healthier

  • What’s a safer, healthier option to alcohol? That would be cannabis, say 90 per cent of Americans asked about their use of substances last year.
  • The findings seem to reflect that people trying to adopt healthier lifestyles are thinking cannabis could be a better fit than alcohol, suggests an article by Merry Jane.

By Angela Stelmakowich

A healthier lifestyle was among four factors associated with more people consuming weed in 2019 than in 2018. The other three factors include there being less stigma around cannabis, legalization and decriminalization efforts, and pot from legal U.S. states being sold on the black market in states where cannabis is still a no-no.

The National Cannabis Study, released last month by marketing research firm MRI-Simmons, notes the single-year jump in cannabis consumption between 2018 and 2019 was significant. About 22 per cent of surveyed Americans consumed weed at least once in 2019 compared to 16 per cent in 2018. That represents a 38 per cent hike.

Of those who used cannabis in 2019, the survey shows 17 per cent consumed once a month or more, while seven per cent consumed daily.

Cannabis, herbal supplements and vitamins were all up from 2018 to 2019. / Photo: Christopher Furlong/Getty Images Christopher Furlong/Getty Images

While consumption of cannabis, herbal supplements and vitamins were all up from 2018 to 2019, caffeine and alcohol consumption dropped slightly, both by about three per cent.

About 58 per cent of respondents also said that marijuana should be legal, up from 56 per cent in 2018, and almost two-thirds, 64 per cent, over the age of 18 expect marijuana to become legalized in all states within the next five years.

The study used a nationally representative online sample of more than 5,000 respondents.

Source: https://www.thegrowthop.com/cannabis-news/cannabis-continuing-to-mainstream-with-more-americans-using-weed-in-2019

Primo Nutraceuticals Inc. $PRMO.ca Receives Site License from Health Canada $CROP.ca $VP.ca NF.ca $MCOA

Posted by AGORACOM-JC at 7:22 AM on Friday, May 15th, 2020
  • Received the ability to import Hand Sanitizer for the duration of the COVID-19 emergency response from the Health Products and Food Branch of Health Canada
  • Site License Number: COV0950 was issued by the Natural and Non-prescription Health Products Directorate of Health Canada

VANCOUVER, British Columbia, May 15, 2020  — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce that it has received the ability to import Hand Sanitizer for the duration of the COVID-19 emergency response from the Health Products and Food Branch of Health Canada.

“This license specifically authorizes the license-holder to manufacture, package, label and/or import “antiseptic Skin Cleansers/Hand Sanitizers” as described in the Product Monograph provided by Primo Nutraceuticals Inc., to Health Canada. The following site is considered to-be-in compliance with GMP requirements outlined in PART 3 of the Natural Health Products Regulations. Activities include: Importing to Canada and Manufacturing, Packaging and Labeling from the U.S.A.”

Site License Number: COV0950 was issued by the Natural and Non-prescription Health Products Directorate of Health Canada to Primo Nutraceuticals Inc. (CSE:PRMO) on April 21st, 2020.

Further to the press release dated March 24, 2020, where Primo signed a production order with Celebrity Driven Brand Beauty Kitchen to provide 1,000 units of free non-hydroalcoholic hand sanitizer. The hand sanitizer will be produced by beauty kitchen, located at 1512 Industrial Rd. Boulder City, Nevada. The production Facility currently has the capacity to produce $450,000USD of product per month. The relationship with Beauty Kitchen has allowed Primo to private label most of Beauty Kitchens product line. This allows Primo to produce product without the construction of its own facility.

The initial run of 1,000 units was financed internally. Future production orders will be financed as procurement orders from the health industry are received. The company will entertain options for equity financing once orders start to come in. The sample of 1,000 units will be handed out to hospital and health care industry professionals.

The management team and Board of Directors at Primo have decided that after handing out all 1,000 units, the hand sanitizer will be made available for purchase directly from the Company’s online shop at:www.primoceuticals.com/shop Users of the site may also notice that the Company has recently added to the shop a ready to purchase Primo branded, breathable, washable and re-usable neck gaiter/face mask that can be used in assisting to combat the virus.

Andy Jagpal, President Comments

“This is an absolute win for the company. We have joined companies like Purell who have been permitted to provide these essential products to combat the spread of the Corona virus. Our goal is to be able to bid on procurement contracts from government hospitals and nursing home facilities as soon as our 1,000 sample hand sanitizer arrive.”

“I would also like to add, if you’re a private corporation, healthcare center, pharmacy or any type of business that requires hand sanitizer to fight against the virus, we ask that you send your requests to Primo at: [email protected] so that we can fulfill those orders without delay.”

About Primo Nutraceuticals

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis related products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of “Primo” branded retail outlets – offering “Thrive,” “Primo,” and a selection of curated partner brands. The Company possesses proprietary formulas for cannabis edibles, topical, and tinctures. Primo is focused on building a strong presence in the hemp industry with the objective of extracting and selling cannabinoids (CBD) products in both Canada and the United States.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

“Andy Jagpal”

President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected]

To learn more about what this news means to the shareholders visit:

Shop:www.primoceuticals.com

www.twitter.com/prmonutra

www.thrivecbd.org

www.beautykitchen.net

www.drinkdefy.com

Corporate:www.primonutraceuticals.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.No regulatory authority has approved or disapproved the information contained in this news release.UnfollowRecommend

Empower Clinics $CBDT.ca and EuroLife Brands $EURO.ca Close Definitive Agreement and Sign Multi-Year Multi-National Licence Agreement $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:13 AM on Friday, May 15th, 2020
  • Empower Clinics to power online education platform for patients, retail locations, national tele-medicine platform and their expanding network of franchisees with EuroLife’s Cannvas.me
  • Under the terms of the agreement, Empower has been granted an exclusive license of the Cannvas.me platform in the United States and Mexico with an option to expand to other jurisdictions

VANCOUVER, BC / May 15th, 2020 / EMPOWER CLINICS INC. (CSE: CBDT) (OTC: EPWCF) (Frankfurt 8EC) (“Empower” or the “Company“), a vertically integrated life sciences company, is pleased to announce that further to the letter of intent announced on February 25, 2020 it has signed a definitive agreement with EuroLife Brands (“EuroLife”), a vertically integrated enterprise focused on the pan-European hemp, cannabinoid, and health and wellness sector. The agreement grants Empower an exclusive license to EuroLife’s “Cannvas.me” cloud based online educational platform in certain international jurisdictions. Empower will use the web-based education technology platform to deliver brand, product, and industry knowledge to employees and over 165,000 patients across Empower’s six corporate clinics in Arizona, Oregon, its first franchise in Oklahoma and nationwide tele-health platform.

Under the terms of the agreement, Empower has been granted an exclusive license of the Cannvas.me platform in the United States and Mexico with an option to expand to other jurisdictions. The agreement includes a three-year term with a three-year renewable option. A licensing fee will be paid over the life of the agreement, consisting of a mixture of cash and stock totalling $460,000 CAD and includes comprehensive service level agreements from EuroLife and ongoing support from EuroLife team roles including VP of Technology, Senior Developer, Quality Assurance, Creative Designer, Program Management, Account Management and regular support from EuroLife’s CEO.

“We needed a robust platform to reach our growing network of owned and franchised locations across the United States and EuroLife’s Cannvas.me education platform exceeds all of our requirements,” said Steven McAuley, chairman and chief executive officer of Empower. “We now have the ability to reach our employees and the patients they serve through a safe, secure and informative online education portal. I believe the ability to deliver consistent product education quickly and efficiently is a competitive advantage that we will leverage as we continue to grow our patient count and number of locations.”

“I am very pleased to announce the agreement with Empower to license our Cannvas.me education portal to reach both employees and medical and retail consumers on an incredibly efficient basis,” said Shawn Moniz, Chief Executive Officer, EuroLife Brands Inc. “I look forward to working with Steven and his incredible team at Empower as they expand their footprint across the United States.”

Cannvas.me is a consumer education portal launched in 2018 for medical and recreational cannabis consumers. Through many discussions with industry stakeholders the management team discovered there was significant demand for a cloud-based education portal for licensed producers, retail dispensaries and other large to mid-sized companies in the cannabis sector.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The Company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company now offers COVID-19 testing options in the United States and physician-based consultations, to address COVID-19 concerns.

About EuroLife Brands Inc.

EuroLife Brands is a leading global markets cannabis brand empowering the medical, recreational and CPG cannabis industry worldwide through a data-driven CBD marketplace supported by exclusive and unbiased physician-backed cannabis education and detailed consumer analytics.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

CEO

[email protected]

604-789-2146

Investors: Dustin Klein

SVP, Business Development

[email protected]

720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws.All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding: the Company’s expected timing of filing of its Annual Filings, the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four of COVID-19 test programs, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.